These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma. Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660 [TBL] [Abstract][Full Text] [Related]
4. Cemiplimab in cutaneous squamous cell carcinomas (SCC): an overview and a clinical case. Ghidini A; Santangelo D; Vaccaro G; Chillura M; Petrelli F Oral Oncol; 2022 May; 128():105847. PubMed ID: 35367788 [TBL] [Abstract][Full Text] [Related]
5. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma. Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175 [No Abstract] [Full Text] [Related]
6. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979 [TBL] [Abstract][Full Text] [Related]
7. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. Rischin D; Khushalani NI; Schmults CD; Guminski A; Chang ALS; Lewis KD; Lim AM; Hernandez-Aya L; Hughes BGM; Schadendorf D; Hauschild A; Thai AA; Stankevich E; Booth J; Yoo SY; Li S; Chen Z; Okoye E; Chen CI; Mastey V; Sasane M; Lowy I; Fury MG; Migden MR J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413166 [TBL] [Abstract][Full Text] [Related]
8. Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma. Hanania HL; Lewis DJ Expert Rev Anticancer Ther; 2022 Feb; 22(2):237-238. PubMed ID: 34918605 [No Abstract] [Full Text] [Related]
9. Maintenance of clinical response after short treatment with cemiplimab for advanced squamous cell carcinoma. Conforti C; Toffoli L; Agozzino M; Fedele D; Moroso S; di Meo N; Zalaudek I J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e443-e445. PubMed ID: 35037322 [No Abstract] [Full Text] [Related]
12. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Villani A; Ocampo-Garza SS; Potestio L; Fabbrocini G; Ocampo-Candiani J; Ocampo-Garza J; Scalvenzi M Expert Opin Drug Saf; 2022 Jan; 21(1):21-29. PubMed ID: 34644510 [TBL] [Abstract][Full Text] [Related]
13. Radiation recall during cemiplimab therapy for locally advanced cutaneous squamous cell carcinoma. Vaccaro M; Bertino L; Santarpia M; Altavilla G; Cannavò SP Dermatol Ther; 2020 Nov; 33(6):e14417. PubMed ID: 33068047 [No Abstract] [Full Text] [Related]
14. Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma. Keeping S; Xu Y; Chen CI; Cope S; Mojebi A; Kuznik A; Konidaris G; Ayers D; Sasane M; Allen R; Huynh TM; Popoff E; Freeman M; Andria ML; Fury MG; Singh K; Stockfleth E; Challapalli A; Schmults CD Future Oncol; 2021 Feb; 17(5):611-627. PubMed ID: 33052055 [No Abstract] [Full Text] [Related]
15. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel. Lebas E; Marchal N; Rorive A; Nikkels AF Expert Rev Anticancer Ther; 2021 Apr; 21(4):355-363. PubMed ID: 33554680 [TBL] [Abstract][Full Text] [Related]
16. Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma. Lee A; Duggan S; Deeks ED Drugs; 2020 Jun; 80(8):813-819. PubMed ID: 32306208 [TBL] [Abstract][Full Text] [Related]
17. RF-Cemiplimab: First Drug Approved for the Treatment of Metastatic or Unresectable Cutaneous Squamous Cell Carcinoma. Morgado-Carrasco D; Bosch-Amate X; Fustà-Novell X; Giavedoni P Actas Dermosifiliogr (Engl Ed); 2020 Mar; 111(2):161-163. PubMed ID: 31874704 [No Abstract] [Full Text] [Related]
18. Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus. Gambichler T; Hessam S; Lüttringhaus T; Boms S Clin Exp Dermatol; 2022 Mar; 47(3):608-609. PubMed ID: 34767651 [TBL] [Abstract][Full Text] [Related]
19. Novel treatment of locally advanced cutaneous squamous cell carcinoma with cemiplimab: a case report. Nelson R; Luu L; Silberstein P; Velagapudi M; Huerter C Int J Dermatol; 2021 Feb; 60(2):233-235. PubMed ID: 32955136 [No Abstract] [Full Text] [Related]